See veebileht kasutab küpsiseid kasutaja sessiooni andmete hoidmiseks. Veebilehe kasutamisega nõustute ETISe kasutustingimustega. Loe rohkem
Olen nõus

Valentina Tefanova

https://etis.ee/CV/Valentina_Tefanova/est
27.09.1949
6593951
valentina.tefanova@tai.ee

Teenistuskäik

Töökohad ja ametid
1997–...   
Tervise Arengu Instituut, Vanemteadur (1,00)
01.01.1997–31.12.2003   
Eksperimentaalse ja Kliinilise Meditsiini Instituut,( EKMI) viroloogia os. vanemteadur
01.01.1988–31.12.1997   
Profülaktilise Meditsiini Instituut (PMI, endine TEMHTUI) viroloogia os. vanemteadur
01.01.1982–31.12.1988   
Tallinna Epidemioloogia, Mikrobioloogia ja Hügieeni TU Instituut(TEMHTUI), viroloogia osakond, nooremteadur
01.01.1979–31.12.1981   
Kliiniline sihtordinatuur laste onkohematoloogia alal, Meditsiiniteaduste Akadeemia Onkoloogiakeskus, Moskva
01.01.1975–31.12.1978   
Tšeljabinskii sünnitusmaja, arst-neonatoloog
 
 
Haridustee
1969–1975   
Leningradi Meditsiiniline Pediaatria Instituut,pediaater
 
 
Teadusorganisatsiooniline ja -administratiivne tegevus
PMI-s ja TAI-s(s.h.EKMI-s) töötamise ajal 7 plaanilise teadustöö
läbiviimisel vastutav täitja neljas ja teema juht ühes teadusteemas.
Vastutav täitja neljas ETF grandis( reg.nr.381, 1993, 4218 ja 5961)
Eesti Immunoloogide Seltsi liige, al. 1984-st
Kliinilise Viroloogia Euroopa Seltsi liige, al.1994-st
Eesti Laborimeditsiini Ühingu liige, al.2004-st
 
 
Lisainfo
2004-2008 sihtteema nr.0942657s04 ja 2004-2007 ETF grandi nr.5961 vastutav täitja.Projekti VISBY programmi"Molecular-epidemiology of viral hepatitis A,B and C in Baltic area" raames Rootsi Nakkushaiguste Kontrolli Instituudiga - täitja

Kvalifikatsioon

Teaduskraadid
Valentina Tefanova, doktorikraad, 1987, (juh) Ljudmilla Priimägi, Sageli haigestuvate laste immuunsusnäitajate hindamine ning nende muutumise dünaamika ägedate respiratoorsete haiguste ennetamisel mittespetsiifiliste vahendite abil, N.I.Pirogovi nim. Meditsiini instituut, Moskva.
 
 
Teaduspreemiad ja tunnustused
2010, Valentina Tefanova, omistati nimetus „Leading Health Professionals of the World, 2010“ (Rahvusvahelise Biograafiakeskuse poolt, Cambridge, Inglismaa
 
 
Teadustöö põhisuunad
ETIS KLASSIFIKAATOR: 3. Terviseuuringud; 3.7. Kliiniline meditsiin; TÄPSUSTUS: B-ja C-viirushepatiitide immunoepidemioloogilised omadused riskirühmades. Immuunsüsteemi erinevad aspektid viirushepatiitide korral. Molekulaar-epidemioloogilised uuringud viirushepatiitide puhul Eestis.
 
 
Lisainfo
Mai 1990,omistatud vanemteaduri kutse allergoloogia ja immunoloogia alal

Lõppenud projektid

Juhendatud väitekirjad

Publikatsioonid

Klass
Aasta
Publikatsioon
 
1.1.
2014
Wiessing, L.; Ferri, M.; Grady, B.; Kantzanou, M.; Sperle, I.; Cullen, KJ.; Busch, M.; Bollaerts, K.; Bogdanova, V.; Nesheva, E.; Fotsiou, N.; Kostrikis, L.; Mravčík, V.; Řehák, V.; Částková, J.; Hobstová, J.; Nechanská, B.; Fouchard, J.; Abel-Ollo, K.; Tefanova, V. ... Matheï, C. (2014). C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS ONE, 1−19.10.1371/journal.pone.0103345.
5.2.
2014
Tefanova, V.; Ivanova, A.; Reshetnjak, I.; Muravjova, J.; Velström, K.; Jokelainen, P.; Lassen, B.; Golovljova, I. (2014). Hepatitis E virus in the Estonian wild boars population. 17th Annual meeting of ESCV, September 28.- October 1, 2014, Praha, Tšehhi. Book of abstracts.. , 85.
1.1.
2013
Kuznetsova, Tatiana; Tallo, Tatjana; Brjalin, Vadim; Reshetnjak, Irina; Salupere, Riina; Priimägi, Ljudmilla; Katargina, Olga; Smirnova, Maria; Jansons, Juris; Tefanova, Valentina. (2013). Amino Acid Polymorphisms Within the Entire HCV NS5A Region in Estonian Chronic HCV 1b Patients With Different Treatment Response. Hepatitis Monthly, 13 (12), e14481. DOI: 10.5812/hepatmon.14481.
1.1.
2013
Brjalin, Vadim; Salupere, Riina; Tallo, Tatjana; Kuznetsova, Tatiana; Priimägi, Ljudmilla; Tefanova, Valentina. (2013). Predictors of treatment response in patients with hepatitis C 1b genotype. Central European Journal of Medicine, 8 (6), 822−829. DOI: 10.2478/s11536-013-0221-2.
5.2.
2013
Kuznetsova, T.; Tallo, T.; Brjalin, V.; Tefanova, V. (2013). Polymorphism within entire HCV NS5A protein as a possible predictor of treatment response in Estonian chronic HCV 1b patients. HCV animal models and vaccine development symposium, May 16-17, 2013, Tallinn, Estonia. Book of abstracts.. , 42.
5.2.
2013
Tallo, T.; Moor, D.; Reshetnjak, I.; Kuznetsova, T.; Plahhova, T.; Tefanova, V.; Norder, H. (2013). Does the distribution of HBV strains in blood donors reflect that of HBV strains circulating in the general population? 5th European Congress of Virology, September 11-14, 2013, Lyon, France. Book of abstracts.. , 228.
1.1.
2012
Brjalin, V.; Salupere, R.; Tefanova, V.; Prikk, K.; Lapidus, N.; Jõeste, E. (2012). Sarcoidosis and chronic hepatitis C: A case report. World Journal of Gastroenterology, 18 (40), 5816−5820.10.3748/wjg.v18.i40.5816.
1.1.
2012
Brjalin, V; Salupere, R; Tallo, T; Kuznetsova, T; Priimägi, L; Tefanova, V. (2012). Efficasy of peginterferon alfa-2a and ribavirin combination therapy in treatment-naive Estonian patients with chronic hepatitis C. Central European Journal of Public Health, 20 (2), 150−155.
1.3.
2012
Tefanova, V; Tallo, T; Kuznetsova, T; Priimägi, L; Epštein, J; Kutsar, K. (2012). E-viirushepatiidi viiruse antikehade esinemine Eesti inimestel. Katseuuring. Eesti Arst, 91 (4), 177−180.
1.1.
2011
Roth, W.; Busch, M.; Schuller, A.; Ismay, S.; Cheng, A.; Seed, C.; Jungbauer, C.; Minsk, P.; Sondag-Thull, D.; Wendel, S.; Levi, J.; Fearon, M.; Delage, G.; Xie, Y.; Jukic, I.; Turek, P.; Ullum, H.; Tefanova, V.; Tilk, M.; Reimal, R. ... Reesink, H. (2011). International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. Vox Sanguinis, doi: 10.1111/j.1423-0410.2011.01506.x.
5.2.
2011
Brjalin, V.; Salupere, R.; Tallo, T.; Kuznetsova, T.; Priimägi, L.; Tefanova, V. (2011). Efficacy of Peginterferon alfa-2a and ribavirin combination therapy in treatment-naïve patients with chronic hepatitis C in Estonia. 13th Slavic – Baltic Congress “Saint - Petersburg – Gastro-enterology 2011“, St.- Peterburg 18.05 - 20.05. 2011, ajakiri Gastrojenterologija S.-Peterburg, 2011.. , 2-3, p.M107.
5.2.
2011
Tefanova, V.; Tallo, T.; Reshetnjak, I.; Kuznetsova, T.; Priimägi, L.; Abel-Ollo, K.; Talu, A. (2011). Molecular epidemiology of HCV in population of IDUs in Estonia. 14th Annual meeting of the ESCV, Funchal, Madeira, 21-24 September 2011, Abstract book.. , 121.
5.2.
2011
Tallo, T.; Tefanova, V.; Plahhova, T.; Priimägi, L.; Kuznetsova, T.; Norder, H. (2011). Changes in HCV subtypes distribution in Estonian blood donors, 1999-2009. 14th Annual meeting of the ESCV, Funchal, Madeira, 21-24 September 2011, Abstract book.. , 120.
5.2.
2011
Tallo, T.; Tefanova, V.; Moor, D.; Plahhova, T.; Norder, H. (2011). Changes in HBV subtypes distribution in Estonian blood donors, 1999-2009. 7th Smögen Summer Symposium on Virology. 40.
1.3.
2010
Brjalin, V; Salupere, R; Tallo, T; Priimägi, L; Tefanova, V. (2010). Kroonilise C-hepatiidi haigete viirusevastase ravi tulemused. Eesti Arst, 89 (3), 172−178.
5.2.
2010
Tallo T., Brjalin V., Katargina O., Priimägi L., Salupere R., Isaguliants M., Tefanova V. (2010). Possible predictors for treatment response in Estonian naive patients with chronic HCV infection. Abstract book of 4th European congress of virology: Cernobbio, Como, Italy, April 7-11. 152.
5.2.
2010
Tefanova, V.; Tallo, T.; Rüütel, K.; Reshetnjak, I.; Priimägi, L.; Uusküla, A. (2010). Hepatitis B virus subgenotype D encoded ayw4 prevalent in Estonian IDUs. Abstract book of 4th European congress of virology.: Cernobbio, Como, Italy, April 7-11. , 152.
1.2.
2009
Paat, G. ; Uusküla, A.; Tefanova, V.; Tallo, T.;Priimägi, L.;Ahi, K. (2009). The trends and risk factors for hepatitis B occurrence in Estonia. Central European Journal of Public Health, 17, 108−111.
5.1.
2009
Rüütel, Kristi; Priimagi, Ljudmilla; Tefanova, Valentina; Tallo, Tatjana; Talu, Ave; Abel-Ollo, Katri; Uuskula, Anneli. (2009). HCV prevalence and risk behaviours among injecting drug users in Estonia. In: Journal of Clinical Virology (S24). European Society for Clinical Virology (ESCV) Winter Meeting, Amsterdam, The Netherlands, January 7-10, 2009. Elsevier Sci.
5.2.
2009
Brjalin, V.; Tallo, T.; Priimägi, L.; Tefanova, V.; Salupere, R. (2009). Treatment results of Estonian naive patients with chronic HCV infection. Well-known infections - the hottest features of diagnostics and treatment - Book of Abstracts: 8th Nordic-Baltic congress on infectious diseases, Saint Petersburg, Russia, September 23-26. 17.
5.2.
2009
Tefanova, V.; Tallo, T.; Rüütel, K.; Reshetnjak, I.; Priimägi, L.; Uusküla, A. (2009). Active HBV infection in some Estonian risk groups. Book of abstracts: 8th Nordic-Baltic Congress on Infectious Diseases "Well-known infections - the hottest features of diagnostics and treatment", Saint Petersburg, Russia, September, 23-26. , 71.
1.1.
2008
Tallo, T; Tefanova, V; Priimägi, L; Schmidt, J; Katargina, O; Michailov, M; Mukomolov, S; Magnius, L; Norder, H. (2008). D2: major subgenotype of hepatitis B virus in Russia and the Baltic region. Journal of General Virology, 89, 1829−1839.
5.1.
2008
Rüütel, K.; Priimägi, L.; Tefanova, V.; Tallo, T.; Talu, A.; Abel-Ollo, K.; Uusküla, A. (2008). HCV prevalence and risk factors among injecting drug users in Estonia. Journal of Clinical Virology, 44: Programme and abstracts of European Society for Clinical Virology(ESCV), Winter Meeting, Amsterdam, The Netherlands, January 7-10, 2009. , S24. (Suppl. 1).
1.1.
2007
Tallo, T.; Norder, H.; Tefanova, V.; Krispin, T.; Schmidt, J.; Ilmoja, M.; Orgulas, K.; Pruunsild, K.; Priimägi, L.; Magnius, LO. (2007). Genetic characterization of hepatitis C virus strains in Estonia: fluctuations in the predominating subtype with time. Journal of Medical Virology, 79 (4), 374−382.
5.2.
2007
Tallo, T.; Tefanova, V.; Priimägi, L.; Michailov, M.; Norder, H.; Magnius, L. (2007). Additional criteria support the classification of HBV genotype D into subgenotypes. Programme and Abstracts: 3rd European Congress of Virology, Nürnberg, Germany, September 1-5. 97.
5.2.
2007
Tefanova, V.; Tallo, T.; Priimägi, L. (2007). Trends in the epidemiology of hepatitis A infection in Estonia. Programme and Abstracts: 3rd European Congress of Virology, Nürnberg, Germany, September 1-5. 206.
5.2.
2007
Priimägi, L.; Tefanova, V.; Tallo, T.; Rüütel, K. (2007). Emerging HIV infection in Estonia. Programme and Abstracts: 3rd European Congress of Virology, Nürnberg, Germany, September 1-5. , 176.
1.2.
2006
Tefanova, V.; Tallo, T.; Kutsar, K.; Priimägi, L. (2006). Urgent action needed to stop spread of hepatitis B and C in Estonian drug users. Euro surveillance : European communicable disease bulletin., 11 (1), E060126.3.
3.1.
2006
Tallo, T.; Norder, H.; Tefanova, V.; Krispin, T.; Schmidt, J.; Ilmoja, M.; Orgulas, K.; Pruunsild, K.; Priimägi, L.; Magnius, L. (2006). Genetic chatracterization of hepatitis C virus strains from Estonia. Journal of Clinical Virology: 12th International Symposium on Viral Hepatitis and Liver Disease, Paris, July 1-5. S205.
5.2.
2006
Tallo, T.; Norder, H.; Tefanova, V.; Priimägi, L.; Magnius, L. (2006). Analysis of complete genome of hepatitis B virus isolates from Estonia and the former USSR. Abstracts: 7th Nordic-Baltic Congress on Infectious Diseases, Riga, Latvia, September 18-20. 27.
5.2.
2006
Tefanova, V.; Tallo, T.; Katargina, O.; Priimägi, L. (2006). Shift in seropidemiology of hepatitis A in Estonian population. Abstracts: 7th Nordic-Baltic Congress on Infectious Diseases,Riga, Latvia, September 18-20. 25.
1.2.
2005
Priimägi, L.; Tefanova, V.; Tallo, T.; Schmidt, E. (2005). The role of serum Th1 and Th2 cytokines in patients with chronic hepatitis B and C virus infection. Acta medica Lituanica, 12 (3), 28−31.
1.2.
2005
Tefanova, V., Tallo, T., Kutsar, K., Priimägi, L. (2005). Current trends in the epidemiology of viral hepatitis B and C in Estonia. EpiNorth, 6 (3), 57−61.
3.2.
2005
Priimägi, L.; Tefanova, V.; Tallo, T. (2005). Emerging viral hepatitis B and C in Estonia. G. Berencsi, A.S. Khan, J. Haloužka. Emerging Biological Threat (20−25). . Amsterdam ; Washington, DC: IOS Press. (NATO Science Series. Series I, Life and behavioural sciences; 370).
1.1.
2004
Tallo, T.; Norder, H.; Tefanova, V.; Krispin, T.; Priimagi, L.; Mukomolov, S.; Mikhailov, M.; Magnius, LO. (2004). Hepatitis B virus genotype D strains from Estonia share sequence similarity with strains from Siberia and may specify ayw4. Journal of Medical Virology, 74 (2), 221−227.
1.3.
2004
Tefanova, V.; Tallo, T.; Jaroslavtsev, N.; Kikoš, G.; Krupskaja, L.; Lisitsina, S.; Kutsar, K.; Priimägi, L. (2004). B- ja C-viirushepatiidid - aktuaalne epidemioloogiline probleem Eestis viimasel aastakümnel. Eesti Arst, 83 (3), 738−743.
1.3.
2004
Tefanova, V.; Tallo, T.; Jaroslavtsev, N.; Kikoš, G.; Krupskaja, L.; Lisitsina, S.; Kutsar, K.; Priimägi, L. (2004). B- and C-viirushepatiidid - aktuaalne epidemioloogiline probleem Eestis viimasel aastakümnel. Eesti Arst, 83 (11), 738−743.
5.2.
2004
Priimägi, L.; Tefanova, V.; Tallo, T.; Schmidt, E. (2004). The role of serum Th1 and Th2 cytokines with chronic hepatitis B and hepatitis C virus infection. Euro Virology 2004: 2nd European Congress of Virology,Madrid, Spain, September 5-9. 293.
1.1.
2003
Tallo, T.; Norder, H.; Tefanova, V.; Ott, K.; Ustina, V.; Prukk, T.; Solomonova, O.; Schmidt, J.; Zilmer, K.; Priimagi, L.; Krispin, T.; Magnius, L.O. (2003). Sequential changes in hepatitis A virus genotype distribution in Estonia during 1994 to 2001. Journal of Medical Virology, 70 (2), 187−193.
1.2.
2003
Priimiagi LS, Tefanova VT, Tallo TG, Shmidt EV, Solomonova OV, Tuisk TP. (2003). Immune-regulating Th1- and Th2-cytokines in chronic infections caused by hepatitis B and C viruses. Voprosy Virusologii, 48 (4), 37−40.
1.3.
2003
Tefanova, V.; Priimägi, L.; Tallo, T.; Jaroslavtsev, N. (2003). Hepatitis B and C infection among intravenous drug users in prisons and visitors of anonymous consulting rooms in Estonia: prevalence and risk factors. Connections, 14, 8−9.
1.2.
2002
Tefanova VT, Tallo TG, Priimiagi LS, Kikosh GV, Krupskaia LM, Lisitsyna SA, Noorlind IuP. (2002). Hepatitis A in Estonia (1990-1999). Zhurnal Mikrobiologii, Epidemiologii i Immunologii, 2, 22−26.
1.2.
2002
Priimiagi LS, Tefanova VT, Tallo TG, Shmidt EV, Solomonova OV, Tuisk TP, Kikosh GV, Krupskaia LM, Lisitsyna SA. (2002). Th1-cytokines in chronic hepatitis B and C. Voprosy Virusologii, 47 (3), 23−27.
1.3.
2002
Tallo, T.; Norder, H.; Tefanova, V.; Ott, K.; Zilmer, K.; Solomonova, O.; Schmidt, J.; Priimagi, L.; Krispin, T.; Magnius, L. (2002). A-hepatiidi viirustüvede genotüübid Eestis 1994-2001. Eesti Arst, 81 (9), 58.
1.2.
2001
Tefanova VT, Priimiagi LS, Tallo TG (2001). Functional and metabolic activity of peripheral blood neutrophiles in acute viral hepatitis B and C. Zhurnal Mikrobiologii, Epidemiologii i Immunologii, 1, 43−47.
1.1.
2000
Tallo T, Lappalainen M, Tefanova V, Priimagi I (2000). Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C in Northern Estonia. Acta Virologica, 44, 175−178.
1.2.
1999
Tefanova VT, Tallo TG, Priimägi LS, Kikosh GV, Krupskaia LM. (1999). The epidemiological aspects of viral hepatitides in Estonia. Zhurnal Mikrobiologii, Epidemiologii i Immunologii, 2, 39−42.
1.2.
1999
Priimiagi LS, Kremerman IB, Tefanov VT, Tallo TG, Osadchaia GS (1999). Functional status of the interferon system in inapparent and clinical infection with hepatitis B and C viruses. Voprosy Virusologii, 44 (2), 85−88.
1.2.
1999
Priimiagi LS, Kremerman IB, Tallo TG, Tefanova VT, Luman MG, Osadchaia GS. (1999). Interferon system status in hemodialysis patients infected with hepatitis B and C viruses. Voprosy Virusologii, 44 (4), 167−169.
1.3.
1993
Tefanova, V.; Kremerman, I.; Priimägi, L.; Redko, L.; Kurvinen, E.; Mordvinova, H.; Pilar, M.. (1993). Eesti põlevkivibasseini laste tervise kliinilis-immunoloogiline iseloomustus. Eesti Arst, 3, 168−171.
22.04.2019

Valentina Tefanova

https://etis.ee/CV/Valentina_Tefanova/eng
27.09.1949
6593951
valentina.tefanova@tai.ee

Career

Institutions and positions
01.01.1997–31.12.2003   
NIHD (former Estonian Institute of Experimental and Clinical Medicine), Virology Dept., senior researcher, 1997 till now
01.01.1988–31.12.1997   
Institute of Preventive Medicine (former TRI EMH), Virology Dept., senior researcher, 1988-1997
01.01.1982–31.12.1988   
Tallinn Research Institute of Epidemiology, Microbiology and Hygiene(TRI EMH) Virology Department, junior researcher, 1982-1988
 
 
Education
1969–1975   
Leningrad´s Pediatric Medical Institute,MD, 1975
 
 
R&D related managerial and administrative work
Working at the IPM and NIHD the executor in seven scientific themes and once as the principal investigator.Co-executor in four grants of Estonian Science Foundation
The member of Estonian Society for Immunology, from 1984
The member of European Society for Clinical Virology, from 1994
The member of Estonian Society for Laboratory Medicine, from 2004

Qualifications

Academic degrees
Valentina Tefanova, Doctor's Degree, 1987, (sup) Ljudmilla Priimägi, Sageli haigestuvate laste immuunsusnäitajate hindamine ning nende muutumise dünaamika ägedate respiratoorsete haiguste ennetamisel mittespetsiifiliste vahendite abil (Evaluation of immune indexes in frequently affected children and dynamics of their changes under preventive measures of acute respiratory diseases by nonspecific means), N.I.Pirogovi nim. Meditsiini instituut, Moskva.
 
 
Fields of research
ETIS CLASSIFICATION: 3. Health; 3.7. Clinical Medicine; SPECIFICATION: Immunoepidemiology of viral hepatitis B and C in risk groups of population.Functional state of immune system at the various course of viral hepatitis.Molecular epidemiology of viral hepatitis in Estonia.
 
 
Additional information
Ph.D., Immunology and Allergology and Virology
N.I.Pirogov Medical Institute, Moscow, 1987
May,1990,attributed the rank of senior researcher in Immunology and Allergology

Completed projects

Supervised dissertations

Publications

Category
Year
Publication
 
1.1.
2012
Brjalin, V; Salupere, R; Tallo, T; Kuznetsova, T; Priimägi, L; Tefanova, V. (2012). Efficasy of peginterferon alfa-2a and ribavirin combination therapy in treatment-naive Estonian patients with chronic hepatitis C. Central European Journal of Public Health, 20 (2), 150−155.
1.1.
2011
Roth, W.; Busch, M.; Schuller, A.; Ismay, S.; Cheng, A.; Seed, C.; Jungbauer, C.; Minsk, P.; Sondag-Thull, D.; Wendel, S.; Levi, J.; Fearon, M.; Delage, G.; Xie, Y.; Jukic, I.; Turek, P.; Ullum, H.; Tefanova, V.; Tilk, M.; Reimal, R. ... Reesink, H. (2011). International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. Vox Sanguinis, doi: 10.1111/j.1423-0410.2011.01506.x.
1.2.
2009
Paat, G. ; Uusküla, A.; Tefanova, V.; Tallo, T.;Priimägi, L.;Ahi, K. (2009). The trends and risk factors for hepatitis B occurrence in Estonia. Central European Journal of Public Health, 17, 108−111.
1.1.
2008
Tallo, T; Tefanova, V; Priimägi, L; Schmidt, J; Katargina, O; Michailov, M; Mukomolov, S; Magnius, L; Norder, H. (2008). D2: major subgenotype of hepatitis B virus in Russia and the Baltic region. Journal of General Virology, 89, 1829−1839.
1.1.
2007
Tallo, T.; Norder, H.; Tefanova, V.; Krispin, T.; Schmidt, J.; Ilmoja, M.; Orgulas, K.; Pruunsild, K.; Priimägi, L.; Magnius, LO. (2007). Genetic characterization of hepatitis C virus strains in Estonia: fluctuations in the predominating subtype with time. Journal of Medical Virology, 79 (4), 374−382.
22.04.2019

Otsi projekti

  • {{item.Name}}
Asutus on projekti finantseerija   Asutus on projekti teostaja  
  • {{searchListItem.Name}}
Kõik   Tavaprojektid   Ülemprojektid   Alamprojektid  
Uus Frascati (2015)
Uus ja vana Frascati (otsing uue järgi väljastab ka seotud vanad)
Kõik
Käimasolevad
Lõppenud
Algus
Hajus
Täpne
Lihtotsing Tühjenda
  • Leitud 7 kirjet
ProgrammLiikNumberNimiProjekti algusProjekti lõppVastutav täitjaAsutusFinantseerijapoolne rahastamine
ETFETF7650Eesti C-hepatiidiviiruse isolaatide geneetiline varieeruvus ja viirusevastase ravi tulemus kroonilistel hepatiidihaigetel01.01.200831.12.2011Valentina TefanovaTervise Arengu Instituut59 514,48 EUR
SFSF0942657s04EESTIS LEVIVATE LOODUSLIKU LEVIKUGA PUUKENTSEFALIIDI- JA HANTAVIIRUSTE NING A-, B- JA C-HEPATIIDIVIIRUSTE MOLEKULAAR-EPIDEMIOLOOGIA JA GENEETILINE ISELOOMUSTUS01.01.200431.12.2008Ljudmilla PriimägiTervise Arengu Instituut304 219,46 EUR
SFSF0940033s09Emergeeruvate zoonooside tekitajad ja hepatotroopsed viirused Eestis: olemasolu, levik, kooseksisteerimine, geneetiline iseloomustus, tähendus inimese haigestumisele.01.01.200931.12.2014Irina GolovljovaTervise Arengu Instituut503 733,24 EUR
MUUVIR.HIV-HEPHIV-i ja hepatiidi levimus, riskikäitumine, teadmised ja hoiakud Eesti vanglates.01.07.200631.01.2008Ljudmilla PriimägiTervise Arengu Instituut154 451,25 EUR
ETFETF5961Molekulaar-epidemioloogiline uuring Eestis isoleeritud B-hepatiidiviiruse genotüüpide leviku ja kliinilise tähtsuse väljaselgitamiseks01.01.200431.12.2007Ljudmilla PriimägiTervise Arengu Instituut29 612,90 EUR
MUUVIR TerVE 2012Zoonoosidesse nakatumisrisk Eestis: puukidega ülekantavad haigustekitajad ja E-hepatiidiviiruse looduskollete ning endeemiliste piirkondade kaardistamine ja iseloomustamine (ZoonRisk)01.02.201231.05.2015Irina GolovljovaTervise Arengu Instituut32 667,00 EUR
IUTIUT42-1Zoonootilised ja hepatotroopsed patogeenid Eestis: uued ja vanemad emergeeruvad nakkused ning nende mõju rahvastiku tervisele01.01.201531.12.2020Irina GolovljovaTervise Arengu Instituut334 200,00 EUR